This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

"Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2009 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00960817
First received: August 17, 2009
Last updated: NA
Last verified: August 2009
History: No changes posted
  Purpose
The investigators will investigate patients undergoing coronary angiography with normal coronary but slow blood flow that was normalized after adenosine injection into the coronary artery. The investigators believe that they have small vessel coronary disease which is the initial presentation of coronary disease prior to anatomical narrowing. To alleviate this phenomenon the investigators intend to examine the long-term clinical response of these patients to treatment with dipyridamole, a well-known medication with almost no side-effects that increases the level of adenosine in the tissue.

Condition Intervention Phase
Coronary Angiography Drug: Statin, aspirin Drug: Dipyridamole Early Phase 1

Study Type: Interventional
Official Title: "Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • Alleviation of chest pain [ Time Frame: Two years ]

Arms Assigned Interventions
Active Comparator: 1. Routine treatment
Control group
Drug: Statin, aspirin
Experimental: 2. Dipyridamole treatment
Group that receives Dipyridamole treatment
Drug: Dipyridamole

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing coronary angiography and who have normal coronary artery with slow blood flow that normalized with adenosine injection into the coronary artery

Exclusion Criteria:

  • Significant coronary disease
  • Unstable patients
  • Patients with known sensitivity to dipyridamole
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00960817

Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Principal Investigator: Aaron Frimerman, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

Responsible Party: Aaron Frimerman, MD, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT00960817     History of Changes
Other Study ID Numbers: HYMC 02/2009
Study First Received: August 17, 2009
Last Updated: August 17, 2009

Keywords provided by Hillel Yaffe Medical Center:
Normal coronary artery with slow blood flow

Additional relevant MeSH terms:
Adenosine
Dipyridamole
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Platelet Aggregation Inhibitors

ClinicalTrials.gov processed this record on September 19, 2017